<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03199872</url>
  </required_header>
  <id_info>
    <org_study_id>RhoVac-001</org_study_id>
    <nct_id>NCT03199872</nct_id>
  </id_info>
  <brief_title>RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours</brief_title>
  <official_title>A Phase I/II Study of RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RhoVac APS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dantrials Aps</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>RhoVac APS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate safety and immunological response to RhoC peptide vaccine in patients
      with prostate cancer
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 30, 2017</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>8 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunological response</measure>
    <time_frame>20 months</time_frame>
    <description>Immune cell response</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>RV001V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RV001 Vaccine 0.1 mg/mL (RV001V). RV001V consists of the peptide RV001 and the adjuvant Montanide ISA 51.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RV001V</intervention_name>
    <description>Sc injection</description>
    <arm_group_label>RV001V</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients prostatectomised (PT) due to histologically verified adenocarcinoma of the
             prostate gland who currently are not being treated, or expected within the next 8
             months to be treated, with any anti-cancer treatment.

          -  ECOG performance status 0 or 1.

        Exclusion Criteria:

          -  Patient has been treated with Androgen Deprivation Therapy (ADT), or expected to
             receive such treatment within the next 8 months from enrolment.

          -  Severe medical conditions, such as but not limited to severe asthma/chronic
             obstructive pulmonary disease (COPD), New York Heart Association (NYHA) grading 3 or
             above, poorly regulated insulin dependent diabetes, any significant organ damage as
             judged by the Investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesper Sonne, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dantrials Aps</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2017</study_first_submitted>
  <study_first_submitted_qc>June 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2017</study_first_posted>
  <last_update_submitted>July 2, 2017</last_update_submitted>
  <last_update_submitted_qc>July 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

